A Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This protocol is designed to develop a novel first-in-class treatment for use in critical
care and life-threatening condition of hypovolemic shock with unmet need and is of national
interest. Shock is a life-threatening condition of circulatory failure. It is a state of
cellular and tissue hypoxia due to reduced oxygen delivery and/or increased oxygen
consumption or inadequate oxygen utilization. Shock most commonly occurs when there is
circulatory failure leading to reduced tissue perfusion. There are four types of shock:
distributive, cardiogenic, hypovolemic, and obstructive. However, these are not exclusive,
and many patients with circulatory failure have a combination of more than one form of shock
(multifactorial shock).